Wasatch Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Wasatch Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-14,465	Closed	-$548K	–	377
2016 Q4	$548K	Hold	14,465	–	–	0.01%	330
2016 Q3	$546K	Sell	14,465 -344	-2%	-$7.59K	0.01%	328
2016 Q2	$261K	Hold	14,809	–	–	﹤0.01%	363
2016 Q1	$180K	Sell	14,809 -20,204	-58%	-$320K	﹤0.01%	360
2015 Q4	$853K	Sell	35,013 -6,277	-15%	-$146K	0.01%	339
2015 Q3	$732K	Hold	41,290	–	–	0.01%	338
2015 Q2	$729K	Buy	41,290 +2,849	+7%	+$52.2K	0.01%	353
2015 Q1	$1.21M	Sell	38,441 -38,346	-50%	-$1.11M	0.01%	335
2014 Q4	$2.24M	Sell	76,787 -15,539	-17%	-$394K	0.02%	305
2014 Q3	$1.91M	Buy	92,326 +679	+0.7%	+$13.4K	0.02%	318
2014 Q2	$2.27M	Sell	91,647 -2,541	-3%	-$44K	0.02%	312
2014 Q1	$2M	Sell	94,188 -80,812	-46%	-$1.63M	0.02%	322
2013 Q4	$3.14M	Buy	+175,000	New	+$2.28M	0.03%	285

Other funds holding AERI

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors's AERI Position: Q1 2017 in Review

Wasatch Advisors sold out of Aerie Pharmaceuticals (AERI) in Q1 2017, closing a stake of 14,465 shares — an estimated $548K sold.

Wasatch Advisors first reported a position in AERI in Q4 2013 and held it in 13 quarters. The position peaked at $3.14M in Q4 2013. 159 funds tracked by Wall St. Rank hold AERI as of Q1 2017.

Wasatch Advisors reported no remaining Aerie Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Wasatch Advisors sold 14,465 Aerie Pharmaceuticals shares in Q1 2017, an estimated $548K.
Wasatch Advisors first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 13 quarters.
Wasatch Advisors's Aerie Pharmaceuticals position peaked at $3.14M in Q4 2013.
159 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2017.

Based on Wasatch Advisors's 13F filing for Q1 2017, filed 15 May 2017.